ClinicalTrials.gg
CompletedNCT06354660Updated Mar 5, 2026

Effect of Retatrutide Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

A Phase 3 interventional study of Retatrutide and Placebo in Diabetes Type 2, sponsored by Eli Lilly and Company. Completed at 48 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-05.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
537
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies testing retatrutide in Diabetes Mellitus, Type 2 — none open to participants now, 3 under way, 3 of them phase 3. retatrutide · Diabetes Mellitus, Type 2.

Enrollment
4th of 10
537 · median 301
Started
2024
with 3 others
Phase 3
5 of 10
none open now
Registered
8th of 10
by date
Lead sponsor
10 of 10
Eli Lilly and Company

Among the 10 studies testing retatrutide in Diabetes Mellitus, Type 2, this one is the 4th largest by enrollment, is one of 4 that started in 2024, is one of 5 in phase 3, and was the 8th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 10 studies testing retatrutide in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About retatrutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing retatrutide in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with placebo in participants with Type 2 Diabetes and inadequate glycemic control. The study will last about 11 months and may include up to 11 visits.

03

Conditions studied

  • Diabetes Type 2

Keywords

  • Glucose Metabolism Disorders
  • Metabolic Diseases
  • Endocrine System Diseases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have Type 2 Diabetes (T2D)
  • Have ≥ 7.0% to ≤ 9.5%
  • Are naïve to insulin therapy and have not used oral or injectable antihyperglycemic (diabetes) medication for at least 90 days prior to screening
  • Are of stable weight for at least 90 days prior to screening
  • Have a (BMI) ≥ 23.0 kilograms per meter squared (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Have Type 1 Diabetes (T1D)
  • Have a history of ketoacidosis or hyperosmolar state or coma within the last 6 months prior to screening
  • Have a history of severe hypoglycemia or hypoglycemia unawareness within the last 6 months prior to screening
  • Are currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema
  • Have an estimated (eGFR) \<15 milliliters/minute/1.73 meter squared (mL/min/1.73 m\^2) as determined by the central laboratory
  • Have a prior or planned surgical treatment for obesity
  • Have Functional Classification IV congestive heart failure
  • Have had an acute myocardial infarction, stroke, or were hospitalized for congestive heart failure within 90 days prior to screening
  • Have a known gastric emptying abnormality
  • Have a history of an active or untreated or are in remission from a clinically significant malignancy for less than 5 years
  • Have any lifetime history of a suicide attempt
  • Had chronic or acute pancreatitis
  • Have a family or personal history of medullary thyroid carcinoma or multiple endocrine neoplasia (MEN) syndrome Type 2
  • Have taken prescribed or over-the-counter medication, or alternative remedies, intended to promote body weight reduction within 90 days prior to screening.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
537 participants (actual)

Study arms

  • Experimental
    Retatrutide Dose Level 1

    Participants will receive retatrutide administered subcutaneously (SC).

    Drug: Retatrutide

  • Experimental
    Retatrutide Dose Level 2

    Participants will receive retatrutide administered SC.

    Drug: Retatrutide

  • Experimental
    Retatrutide Dose Level 3

    Participants will receive retatrutide administered SC.

    Drug: Retatrutide

  • Placebo comparator
    Placebo

    Participants will receive placebo administered SC.

    Drug: Placebo

Interventions

  • Administered SC.

    Also known as: LY3437943

  • DrugPlacebo

    Administered SC.

06

What researchers measure

Primary outcomes

  1. Change from Baseline in Hemoglobin A1c (HbA1c) (%)

    Time frame: Baseline, Week 40

Secondary outcomes

  1. Percentage of Participants Who Achieve HbA1c < 7.0%

    Time frame: Week 40

  2. Percentage of Participants Who Achieve HbA1c ≤ 6.5%

    Time frame: Week 40

  3. Percentage of Participants Who Achieve HbA1c < 5.7%

    Time frame: Week 40

  4. Change from Baseline in Fasting Serum Glucose

    Time frame: Baseline, Week 40

  5. Percent Change from Baseline in Body Weight

    Time frame: Baseline, Week 40

  6. Change from Baseline in Body Weight

    Time frame: Baseline, Week 40

  7. Percentage of Participants Who Achieve Weight Reduction of ≥ 5%

    Time frame: Week 40

  8. Percentage of Participants Who Achieve Weight Reduction of ≥ 10%

    Time frame: Week 40

  9. Percentage of Participants Who Achieve Weight Reduction of ≥ 15%

    Time frame: Week 40

  10. Percentage of Participants Who Achieve HbA1c ≤ 6.5% and ≥ 10% Weight Reduction

    Time frame: Week 40

  11. Percent Change from Baseline in Triglycerides

    Time frame: Baseline, Week 40

  12. Percent Change from Baseline in Non- High-Density Lipoprotein (HDL) Cholesterol

    Time frame: Baseline, Week 40

  13. Change from Baseline in Systolic Blood Pressure (SBP)

    Time frame: Baseline, Week 40

07

Study locations

48 sites
  • Scottsdale Clinical Trials
    Scottsdale, Arizona 85260, United States
  • Tucson Clinical Research Institute
    Tucson, Arizona 85712, United States
  • San Fernando Valley Health Institute
    Canoga Park, California 91304, United States
  • Ark Clinical Research
    Long Beach, California 90815, United States
  • Northeast Research Institute (NERI)
    Fleming Island, Florida 32003, United States
  • New Horizon Research Center
    Miami, Florida 33165, United States
  • Ezy Medical Research
    Miami, Florida 33175, United States
  • Clinical Research of Central Florida
    Winter Haven, Florida 33880, United States
  • Trinity Research Centers
    Marietta, Georgia 30064, United States
  • Cotton O'Neil Clinical Research Center
    Topeka, Kansas 66606, United States
  • NECCR PrimaCare Research
    Fall River, Massachusetts 02721, United States
  • Clinical Research Professionals
    Chesterfield, Missouri 63005, United States
  • Boeson Research MSO
    Missoula, Montana 59804, United States
  • NJ MedCare & NJ Heart
    Linden, New Jersey 07036, United States
  • Accellacare - Wilmington - 1917 Tradd Court
    Wilmington, North Carolina 28401, United States
  • Providence Health Partners-Center for Clinical Research
    Dayton, Ohio 45439, United States
  • Clinical Research of Philadelphia
    Philadelphia, Pennsylvania 19114, United States
  • Preferred Primary Care Physicians
    Uniontown, Pennsylvania 15401, United States
  • Delricht Research - Tobias Gadson Boulevard - Charleston
    Charleston, South Carolina 29407, United States
  • Lifedoc Research - Lenox Park Drive
    Memphis, Tennessee 38115, United States
  • Clinical Research Associates Inc
    Nashville, Tennessee 37203, United States
  • Velocity Clinical Research, Dallas
    Dallas, Texas 75230, United States
  • Prime Revival Research Institute, LLC
    Flower Mound, Texas 75028, United States
  • Valley Institute of Research - Fort Worth
    Fort Worth, Texas 76164, United States
  • Consano Clinical Research, LLC
    Shavano Park, Texas 78231, United States
  • Texas Valley Clinical Research
    Weslaco, Texas 78596, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • MultiCare Rockwood Cheney Clinic
    Cheney, Washington 99004, United States
  • Eastside Research Associates
    Redmond, Washington 98052, United States
  • All India Institute of Medical Sciences
    Raipur, Chhattisgarh 492099, India
  • Gujarat Endocrin Pvt Ltd
    Ahmedabad, Gujarat 380052, India
  • Nirmal Hospital Pvt Ltd.
    Surat, Gujarat 395002, India
  • Victoria Hospital, Bangalore Medical College And Research Institute
    Bangalore, Karnataka 560002, India
  • Government Medical College - Kozhikode
    Kozhikode, Kerala 673008, India
  • All India Institute of Medical Sciences
    Bhubaneswar, Odisha 751019, India
  • Eternal Heart Care Center and Research Institute
    Jaipur, Rajasthan 302020, India
  • Brij Medical Centre Private Limited
    Kanpur, Uttar Pradesh 208020, India
  • Grupo Ollin Care
    Pachuca, Hidalgo 42000, Mexico
  • Instituto Jalisciense de Investigacion en Diabetes y Obesidad
    Guadalajara, Jalisco 04460, Mexico
  • Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
    Mexico City, Mexico City 14080, Mexico
  • Unidad biomedica avanzada monterrey
    Monterrey, Nuevo León 64460, Mexico
  • Clínica García Flores SC
    Monterrey, Nuevo León 64610, Mexico
  • Centro de investigación y control metabólico
    San Nicolás de los Garza, Nuevo León 66465, Mexico
  • EME RED Hospitalaria
    Mérida, Yucatán 97000, Mexico
  • Medical Care and Research SA de CV
    Mérida, Yucatán 97070, Mexico
  • Arké SMO S.A de C.V
    Veracruz, 91910, Mexico
  • Dorado Medical Complex
    Dorado, 00646, Puerto Rico
  • Ponce Medical School Foundation Inc.
    Ponce, 00716, Puerto Rico
08

References and documents

Publications

  • Bajaj HS, Welch M, Shah P, Luna E, Jaouimaa FZ, Liu B, Liu R, Chen Y, Patel H, Bartee A. Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial. Lancet. 2026 Jun 13;407(10546):2402-2413. doi: 10.1016/S0140-6736(26)00967-0. Epub 2026 Jun 6. PubMed 42250575 ↗

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication or approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2024 to primary completion in Jan 2026, 21 months.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 21 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2024
First posted
Apr 9, 2024
StartActual
Apr 10, 2024
Primary completionActual
Jan 22, 2026
CompletionActual
Feb 20, 2026
Last update
Mar 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06354660
Responsible party
Sponsor
First posted
Apr 9, 2024
Start date
Apr 10, 2024
Primary completion
Jan 22, 2026
Completion
Feb 20, 2026
Last update
Mar 5, 2026

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Retatrutide

Start the discussion